MedTrace Logo

Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma

NCT03168035 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2018-02-23

No results posted yet for this study

Summary

The goal of this clinical research study is to find the highest tolerated dose of NC-4016 that can be given to patients with advanced solid tumors or lymphoma. The safety of the drug will also be studied.

Conditions

Interventions

DRUG

NC-4016

Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle. Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group.

Sponsors & Collaborators

  • M.D. Anderson Cancer Center

    collaborator OTHER

  • NanoCarrier Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-04-30
Completion
2017-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03168035 on ClinicalTrials.gov